Rapt Therapeutics (RAPT) Competitors $24.45 +0.50 (+2.09%) Closing price 04:00 PM EasternExtended Trading$23.74 -0.71 (-2.92%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. EVO, AMPH, SNDX, STOK, XERS, ZYME, TRML, LENZ, CVAC, and CALTShould you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Evotec (EVO), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), Stoke Therapeutics (STOK), Xeris Biopharma (XERS), Zymeworks (ZYME), Tourmaline Bio (TRML), LENZ Therapeutics (LENZ), CureVac (CVAC), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Rapt Therapeutics vs. Its Competitors Evotec Amphastar Pharmaceuticals Syndax Pharmaceuticals Stoke Therapeutics Xeris Biopharma Zymeworks Tourmaline Bio LENZ Therapeutics CureVac Calliditas Therapeutics AB (publ) Evotec (NASDAQ:EVO) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability. Is EVO or RAPT more profitable? Rapt Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -20.14%. Evotec's return on equity of -16.94% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Evotec-20.14% -16.94% -8.14% Rapt Therapeutics N/A -67.92%-59.59% Do insiders and institutionals believe in EVO or RAPT? 5.8% of Evotec shares are held by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are held by institutional investors. 1.0% of Evotec shares are held by company insiders. Comparatively, 2.4% of Rapt Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer EVO or RAPT? In the previous week, Evotec and Evotec both had 3 articles in the media. Rapt Therapeutics' average media sentiment score of 1.72 beat Evotec's score of 0.91 indicating that Rapt Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapt Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, EVO or RAPT? Evotec has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Which has better valuation and earnings, EVO or RAPT? Rapt Therapeutics has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$862.40M1.46-$212.18MN/AN/ARapt Therapeutics$1.53M264.32-$129.87M-$14.17-1.73 Do analysts prefer EVO or RAPT? Evotec currently has a consensus target price of $5.40, indicating a potential upside of 52.54%. Rapt Therapeutics has a consensus target price of $21.57, indicating a potential downside of 11.77%. Given Evotec's higher possible upside, research analysts plainly believe Evotec is more favorable than Rapt Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Rapt Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 SummaryRapt Therapeutics beats Evotec on 7 of the 12 factors compared between the two stocks. Get Rapt Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$396.08M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-1.7320.6375.7726.11Price / Sales264.32442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book2.129.6212.876.30Net Income-$129.87M-$52.73M$3.29B$271.03M7 Day Performance19.27%0.64%-0.26%-0.15%1 Month Performance124.72%6.31%3.84%6.41%1 Year Performance73.65%18.97%68.35%28.81% Rapt Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRapt Therapeutics3.2353 of 5 stars$24.45+2.1%$21.57-11.8%+70.1%$396.08M$1.53M-1.7380Positive NewsGap DownEVOEvotec1.5762 of 5 stars$3.75+3.0%$5.40+44.0%+10.1%$1.29B$862.40M0.004,827High Trading VolumeAMPHAmphastar Pharmaceuticals4.2791 of 5 stars$27.89+0.9%$31.60+13.3%-43.3%$1.29B$731.97M10.452,028Positive NewsSNDXSyndax Pharmaceuticals3.9034 of 5 stars$14.89+0.7%$39.22+163.4%-17.9%$1.27B$23.68M-3.83110STOKStoke Therapeutics3.8897 of 5 stars$22.85-0.2%$25.57+11.9%+77.7%$1.25B$36.56M26.88100Positive NewsXERSXeris Biopharma2.2653 of 5 stars$7.86+1.8%$7.08-9.9%+183.7%$1.25B$203.07M-37.43290ZYMEZymeworks2.0342 of 5 stars$16.53+1.7%$21.43+29.6%+30.4%$1.24B$122.87M-11.02460TRMLTourmaline Bio0.8923 of 5 stars$47.75+0.0%$45.65-4.4%+102.8%$1.23BN/A-13.9244Positive NewsLENZLENZ Therapeutics1.5278 of 5 stars$41.26-2.4%$49.60+20.2%+89.2%$1.21BN/A-21.72110CVACCureVac3.9503 of 5 stars$5.36+0.2%$6.83+27.5%+68.0%$1.20B$579.18M5.58880News CoveragePositive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Evotec Competitors Amphastar Pharmaceuticals Competitors Syndax Pharmaceuticals Competitors Stoke Therapeutics Competitors Xeris Biopharma Competitors Zymeworks Competitors Tourmaline Bio Competitors LENZ Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPT Stock Alerts